Key points are not available for this paper at this time.
Bispecific antibodies have been successfully introduced into the management of relapsed or refractory B-cell lymphomas, including DLBCL. Phase 1 studies of the different CD3/CD20 bispecifics have shown manageable safety profile and promising activity in a range of B-cell lymphomas, and recent phase 2 studies confirm the favourable safety and show frequent and durable complete responses even in heavily pre-treated and high-risk patients. This paper discusses the future potential role of these new agents as single agents and in combinations, and their position in the current and future treatment landscape, also in relation to chimeric antigen receptor T-cell therapy.
Martin Hutchings (Thu,) studied this question.